Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma

Gene

Volumn 524, Issue 2, 2013, Pages 156-160

  Son, Myung Su ^a   Jang, Moon Ju ^a   Jeon, Young Joo ^a   Kim, Won Hee ^a   Kwon, Chang Il ^a   Ko, Kwang Hyun ^a   Park, Pil Won ^a   Hong, Sung Pyo ^a   Rim, Kyu Sung ^a   Kwon, Sung Won ^a   Hwang, Seong Gyu ^a   Kim, Nam Keun ^a  

^a CHA University   (South Korea)

Author keywords

Hepatocellular carcinoma; MiR 34b c; Polymorphism; TP53

Indexed keywords

MICRORNA; MIRNA 34B; MIRNA 34C; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GENETICS; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; KOREA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPING TECHNIQUES; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84878646211     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.04.042     Document Type: Article

References (28)

1. Akkiz H., Bayram S., Bekar A., Akgollu E., Ulger Y. A functional polymorphism in pre-microRNA-196a-2 contributes to the susceptibility of hepatocellular carcinoma in a Turkish population: a case-control study. J. Viral Hepat. 2011, 18:e399-e407.
2. Bommer G.T., et al. p53-Mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 2007, 17:1298-1307.
3. Chou J., Provot S., Werb Z. GATA3 in development and cancer differentiation: cells GATA have it!. J. Cell. Physiol. 2010, 222:42-49.
4. El-Serag H.B. Hepatocellular carcinoma. N. Engl. J. Med. 2011, 365:1118-1127.
5. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
6. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010, 17:193-199.
7. Hu Z., et al. Genetic variants of miRNA sequences and non-small cell lung cancer survival. J. Clin. Invest. 2008, 118:2600-2608.
8. Irarrazabal C.E., Rojas C., Aracena R., Marquez C., Gil L. Chilean pilot study on the risk of lung cancer associated with codon 72 polymorphism in the gene of protein p53. Toxicol. Lett. 2003, 144:69-76.
9. Iwai N., Naraba H. Polymorphisms in human pre-miRNAs. Biochem. Biophys. Res. Commun. 2005, 331:1439-1444.
10. Kim W.H., et al. Association study of microRNA polymorphisms with hepatocellular carcinoma in Korean population. Gene 2012, 504:92-97.
11. Kozaki K., Imoto I., Mogi S., Omura K., Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res. 2008, 68:2094-2105.
12. Kuroda Y., Tsukino H., Nakao H., Imai H., Katoh T. p53 codon 72 polymorphism and urothelial cancer risk. Cancer Lett. 2003, 189:77-83.
13. Law P.T., Wong N. Emerging roles of microRNA in the intracellular signaling networks of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2011, 26:437-449.
14. Lee Y.S., Dutta A. MicroRNAs in cancer. Annu. Rev. Pathol. 2009, 4:199-227.
15. Lin J., Horikawa Y., Tamboli P., Clague J., Wood C.G., Wu X. Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis 2010, 31:1805-1812.
16. Lin R.J., Lin Y.C., Yu A.L. miR-149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells. Mol. Carcinog. 2010, 49:719-727.
17. Lujambio A., et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 2007, 67:1424-1429.
18. Lujambio A., et al. A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:13556-13561.
19. Qi P., et al. Association of a variant in MIR 196A2 with susceptibility to hepatocellular carcinoma in male Chinese patients with chronic hepatitis B virus infection. Hum. Immunol. 2010, 71:621-626.
20. Suzuki K., et al. A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J. Biomed. Sci. 2003, 10:430-435.
21. Toyota M., et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008, 68:4123-4132.
22. Wittke-Thompson J.K., Pluzhnikov A., Cox N.J. Rational inferences about departures from Hardy-Weinberg equilibrium. Am. J. Hum. Genet. 2005, 76:967-986.
23. Xiang Y., Fan S., Cao J., Huang S., Zhang L.P. Association of the microRNA-499 variants with susceptibility to hepatocellular carcinoma in a Chinese population. Mol. Biol. Rep. 2012, 39:7019-7023.
24. Xu T., et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis 2008, 29:2126-2131.
25. Xu Y., et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int. J. Cancer 2011, 128:412-417.
26. Yoon Y.J., et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 2008, 29:1192-1196.
27. Yu M.W., et al. Role of reproductive factors in hepatocellular carcinoma: impact on hepatitis B- and C-related risk. Hepatology 2003, 38:1393-1400.
28. Zhu Z.Z., et al. A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection. Cancer Lett. 2005, 229:77-83.